VKTX Stock Recent News
VKTX LATEST HEADLINES
Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage Improvement in Fibrosis with No Worsening of NASH as Compared to 34% for Placebo (p
Biotechs that aspire to be disruptive are quite risky. However, they do offer the chance of disproportionate rewards.
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.
SAN DIEGO , May 30, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. Details of the company's participation are as follows: 2024 Jefferies Global Healthcare Conference Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetingsConference dates: June 5-6, 2024 Presentation Timing: 10:30 – 10:55 a.m.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics develops therapies to treat obesity. Several of its drug candidates showed promising data during phase 2 trials.
Viking has multiple GLP-1 drugs in development that have been generating impressive results. Given this market's potential, its financials could improve dramatically if one of its drugs is approved.
Viking Therapeutics is looking to make noise in a fast-growing therapeutic area. Recursion Pharmaceuticals' approach could change the way we develop drugs.
Viking Therapeutics stock is up by a significant amount this year. It still has key catalysts on the way that investors should note.
Altimmune could have a blockbuster weight-loss drug on the way. Axsome Therapeutics has two products on the market plus multiple promising-pipeline programs.